The 51^st American Society of Hematology [ASH] Annual Meeting will take place December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA. This is the premier event for the hematology industry, attracting more than 20,000 hematologists and other health-care professionals.

In this regard, Celgene Corporation (CELG) recently announced that data from more than 200 clinical trials involving the company’s products will be presented at the ASH annual meeting. After reaching a 52-week low of $36.90 in April 2009, shares of Celgene have rebounded nearly 50% to close at $54.97. As a result, investors may gravitate to other biotechnology companies specializing in the area of hematology to uncover similar investment opportunities.